Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Melanoma 1Lymphoma 1Lung Neoplasms 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Castration-resistant Prostate Cancer 1Breast Neoplasms 1

Interventions

enzalutamide 5abiraterone 2Radiotherapy 2Metastasectomy 2Abiraterone Acetate 2testosterone enanthate 1radium Ra 223 dichloride 1pembrolizumab 1disitamab vedotin 1dactolisib 1VT-464 1Radium-223 1Radiosurgery 1Prednisone 1NVP-BKM120 1Ketoconazole 1Injections 1Hydrocortisone 1Flutamide 1Cyclophosphamide 1Crizotinib 1Control Groups 1Carboplatin 1Calcitriol 1Blood Specimen Collection 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Castration-resistant Prostate Cancer × Crizotinib × Genitourinary × Clear all
NCT02207504 2022-01-06

Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Dana-Farber Cancer Institute

Phase 1 Completed
24 enrolled
Genitourinary

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡